Health Grants

National Institutes of Health · Amount varies

This NIH/NIA K07 career award supports established investigators who lead efforts to build aging and Alzheimer's/dementia research capacity, mentorship, and infrastructure at their academic institution. It is applied for through a research or education institution but effectively targets individual senior investigators; foreign organizations are not eligible, and it does not allow leading an independent clinical trial. No award amount is specified. Applicants should confirm they meet the leadership and career-stage criteria, which are specific.

National Institutes of Health · Amount varies

This NIH/NINDS K22 career-transition award helps NINDS intramural neurologist- and neurosurgeon-scientists move to independent academic faculty positions, with a clinical trial required. It is applied for through a research or education institution but is restricted to NINDS intramural clinician-scientists, making eligibility very narrow; foreign organizations and components are not eligible. No award amount is specified. Most outside applicants will not qualify for this opportunity.

National Institutes of Health · Amount varies

This NIH/NCI R01 funds advanced preclinical research translating nanotechnology-based cancer diagnostics and therapeutics toward later NCI translational programs; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Foreign organizations are not eligible. No award amount is specified, and the nanomedicine focus makes the scope narrow.

National Institutes of Health · Up to $6.3M

Open to a broad range of U.S. research organizations including universities, minority-serving institutions, tribal governments, and faith- and community-based groups under this NICHD UG3/UH3 award (clinical trial optional); foreign organizations are not eligible. Funds investigator-initiated, multisite clinical trials and observational studies on infants, children, women, pregnant and lactating people, and people with disabilities, using existing NICHD network infrastructure. Applications must be submitted with the relevant NICHD Data Coordinating Center as a two-phase, milestone-driven project; total funding can reach roughly $6.25 million.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Up to $100K

This NIH (R03) opportunity funds pilot projects generating preliminary data on a defined list of understudied proteins associated with rare diseases. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $100,000.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds basic, mechanistic research into the biological and genetic causes of cancer health disparities, including new methods, models, and secondary data analyses. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIDDK (R21) opportunity funds basic and translational pilot research on biological, behavioral, and social mechanisms contributing to HIV pathogenesis within NIDDK's mission. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Up to $200K

This NIH (R21) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. The maximum award is about $200,000.

National Institutes of Health · Up to $300K

This NIH (R01) opportunity funds basic research into the harmful effects of acute exposure to ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations, including delayed effects. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $300,000.

National Institutes of Health · Amount varies

This NIH (R21) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH (R01) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R61/R33) phased opportunity funds medical device prototype design and testing, disease-target identification, and assay development for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R33) opportunity funds early-stage translational work to identify and characterize therapeutic candidates and combination products (small molecules and biologics) for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R33) opportunity funds early-stage translational work to optimize medical device prototypes, develop diagnostic assays, and create research tools for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NHLBI Catalyze (R61/R33) phased opportunity funds target identification and validation plus preliminary product or lead-series identification for small molecules, biologics, and combination products treating heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Up to $350K

This NHLBI Catalyze (R33) opportunity funds rigorous validation of transformative, multi-use platforms or technologies that can advance detection, diagnosis, treatment, or prevention of heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $350,000.

National Institutes of Health · Up to $500K

This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of behavioral and social intervention clinical trials for dental, oral, or craniofacial conditions, with a milestone-driven planning phase before transition to a full trial. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible. The maximum award is about $500,000.

National Institutes of Health · Amount varies

This NIDCR (UG3/UH3) cooperative agreement funds planning and implementation of drug, biologic, device, or procedure intervention clinical trials within NIDCR's mission. A clinical trial is required. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.

National Institutes of Health · Amount varies

This NIH SHINE (R01) opportunity supports innovative basic and early translational research in nonmalignant hematology, relevant to NIDDK, NIA, and NHLBI missions. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.